Skip to main content

Table 2 Participant characteristics in HIV cure trials

From: Leveraging early HIV diagnosis and treatment in Thailand to conduct HIV cure research

Study agents RV411 RV397 RV409 RV405
N/A VRC01 Placebo VHM Placebo Ad26/MVA Placebo
Number of participants 8 13 5 10 5 17 9
Median age 29 32 25 28 26 24 25
Male (%) 87.5 100 100 89 75 100 100
Median HIV RNA pre-ART, log10 c/mL 4.3 3.1 2.7 6.1 5.6 5.9 6.4
Median CD4, cells/mm3 pre-ART 413 769 552 397 532 633 586
Median CD4/CD8 ratio pre-ART 0.8 1.1 0.9 0.4 0.8 0.6 0.6
Median duration of ART (years) 2.8 3.1 2.7 4.3 3.0 2.2 2.2
Fiebig stage (number) I: 8 I/II: 8
III: 5
I/II: 3
III: 2
III: 8
IV: 2
III: 5 I: 0
II: 6
III: 6
IV: 5
I: 1
II: 4
III: 4
IV: 0
  1. VHM vorinostat, hydroxychloroquine, maraviroc, Ad26 adenovirus type 26 vector prime, MVA modified vaccinia Ankara, ART antiretroviral therapy